NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
June 22, 2004 • Volume 1 / Number 25 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Combination Chemotherapy for Recurrent Ovarian Cancer

Name of the Trial
Phase III Randomized Study of Carboplatin With or Without Pegylated Doxorubicin HCl Liposome in Patients with Platinum-Sensitive Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (SWOG-S0200). See the protocol summary at

Dr. David Samuel Alberts Principal Investigator
Dr. David Samuel Alberts of the Arizona Cancer Center and the Southwest Oncology Group.

Why Is This Trial Important?
Ovarian epithelial cancer is the leading cause of death from gynecologic malignancies in the United States. Surgery followed by chemotherapy with a platinum-based agent (such as carboplatin) is the standard treatment for advanced stage ovarian epithelial cancer.

Ovarian cancer that remains progression-free for more than 6 months after completion of chemotherapy is called platinum-sensitive. Patients who have a recurrence of platinum-sensitive disease will likely benefit from another round of platinum therapy, which may be given in combination with a non-platinum agent.

Primary peritoneal cancer grows in the peritoneum, a membrane that lines the walls of the abdomen. It is biologically similar to ovarian epithelial cancer.

This trial will study the effectiveness of carboplatin with or without pegylated liposomal doxorubicin in treating patients with recurrent ovarian epithelial or primary peritoneal cancer.

"Whether two-drug combinations are superior to single agent carboplatin in platinum-sensitive disease remains a critical, unanswered question in the management of women experiencing recurrent advanced disease," said Dr. Alberts.

Who Can Join This Trial?
Researchers seek to enroll 900 patients with stage III or IV ovarian epithelial or primary peritoneal cancer. See the full list of eligibility criteria for this trial at

Where Is This Trial Taking Place?
Multiple study sites in the United States are enrolling patients in this trial. See the list of sites at

Who to Contact
See the list of study contacts at or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and completely confidential.

An archive of "Featured Clinical Trial" columns is available at